Programmed cell death ligand-1 (PD-L1) monoclonal antibody
Showing 1 - 25 of >10,000
NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1
Not yet recruiting
- Non-Small Cell Lung Cancer
- Capsulized Fecal Microbiota Transplant
- +2 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Aug 12, 2021
NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Tumor treating fields(EFE-P100)
- Docetaxel injection
-
Shanghai, ChinaShanghai Pulmonary Hospital
Dec 21, 2022
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Paclitaxel
- +4 more
-
Chuo-ku, Tokyo, JapanNational Cancer Center Hospital ( Site 3700)
Jan 31, 2023
Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal
Not yet recruiting
- Nasopharyngeal and Hypopharyngeal Carcinoma
- immunohistochemical
-
Sohag, EgyptSohag University Hospital
Oct 23, 2022
Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)
Not yet recruiting
- Acute Lymphoblastic Leukemia in Pediatric
- flow cytometric immunophynotyping
-
Sohag, EgyptSohag University Hospital
Jun 19, 2022
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,
Recruiting
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Rituximab
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Apr 7, 2023
PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC
Recruiting
- Non-small Cell Lung Cancer
-
Monza, ItalyASST-Monza Ospedale San Gerardo
Jun 9, 2022
Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)
Completed
- Recurrent/Metastatic Gastric Cancer
- Nivolumab, Paclitaxel
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Sep 9, 2022
Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- Atezolizumab
- +2 more
-
Villejuif, Val De Marne, FranceGustave Roussy
Feb 15, 2022
NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- pembrolizumab
- +3 more
- (no location specified)
Aug 18, 2022
Advanced NSCLC Trial (BNT116, Cemiplimab)
Not yet recruiting
- Advanced Non-Small Cell Lung Cancer
- (no location specified)
Jan 3, 2023
NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Sacituzumab Govitecan
- Pembrolizumab
-
Marietta, Georgia
- +2 more
Jan 27, 2023
NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- pembrolizumab
- +3 more
- (no location specified)
Aug 18, 2022
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,
Not yet recruiting
- Non Small Cell Lung Cancer
- +2 more
- Pembrolizumab, pemetrexed, platinum
- Osimertinib
-
Peking, ChinaPeking Union Medical College Hospital
Nov 16, 2023
Tumor-Infiltrating Lymphocytes and Programmed Cell Death -
Recruiting
- Breast Cancer
- +2 more
- Observational Study
-
Lucknow, Uttar Pradesh, IndiaSanjay Gandhi Postgraduate Institute of Medical Sciences
Feb 11, 2022
Extensive Stage Small Cell Lung Cancer Trial in Shanghai (recombinant anti-PD-L1 mAb injection combined with carboplatin and
Recruiting
- Extensive Stage Small Cell Lung Cancer
- recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
May 9, 2022
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite
Completed
- Metastatic Colorectal Adenocarcinoma
- regorafenib plus anti-PD-1 antibodies
-
Changsha, Hunan, ChinaHunan Cancer hospital
Jul 4, 2023
Large B-cell Lymphoma Trial in Groningen (89Zr-atezolizumab PET-imaging)
Recruiting
- Large B-cell Lymphoma
- 89Zr-atezolizumab PET-imaging
-
Groningen, NetherlandsUniversity Medical Center Groningen
Jul 15, 2022
Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib
Enrolling by invitation
- Hepatocellular Carcinoma Non-resectable
- +3 more
- lenvatinib + sindilimab/carrelizumab
- TACE
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
May 23, 2022
Rectal Cancer Stage, Oesophageal Cancer Trial in Vienna (CRT, SCPRT, CROSS Protocol)
Not yet recruiting
- Rectal Cancer Stage
- Oesophageal Cancer
- CRT
- +3 more
-
Vienna, AustriaMedical University of Vienna
Mar 26, 2022
Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,
Recruiting
- Advanced Lung Carcinoma
- LK101 injection (personlized neoantigen pulsed DC vaccine )
- +2 more
-
Beijing, Beijing, ChinaCancer hospital Chinese Academy of Medical Sciences
May 23, 2023